Rising Star Buys: 2 Health Care Winners

This article is part of our Rising Star Portfolios series.

It's time to get some more large-cap exposure in the Rising Stars multivitamin portfolio -- my diversified, well-balanced, complete, one-stop portfolio for all your investing needs that also cures gout.

I'm returning to the same Corporate El Dorados screen that produced our first buy, Coca-Cola. This should give us a nice list of stable dividend-paying blue chips that can stay in the portfolio for years. You can read more about the fantastic long-term performance of these "bear-market protectors" and "return accelerators" here. As for the specific criteria, we'll start with all dividend-paying companies on major U.S. exchanges. They must also pass the following tests:

  1. Market cap greater than $20 billion.
  2. Total debt-to-capital ratio less than 60%.
  3. Average annual earnings-per-share growth over the past 10 years greater than 5%.
  4. Projected annual earnings-per-share growth over the next five years greater than 5%.
  5. Positive dividend growth over the past five years.

The screen spit out 66 companies. Here are some of the more likely candidates:

Company

Market Cap (Millions)

Debt/Capital

 5-Year Growth (Projected)

Dividend Yield

ExxonMobil (NYSE: XOM  )

$433,522

11%

7%

2%

Microsoft

$223,419

17%

12%

2.4%

International Business Machines

$195,345

55%

12%

1.6%

Procter & Gamble (NYSE: PG  )

$179,670

33%

9%

3%

Johnson & Johnson (NYSE: JNJ  )

$165,462

17%

6%

3.6%

Abbott Labs (NYSE: ABT  )

$71,916

46%

9%

4.1%

Total (NYSE: TOT  )

$134,661

33%

13%

4.6%

Schlumberger (NYSE: SLB  )

$126,436

21%

20%

1.1%

Qualcomm (Nasdaq: QCOM  )

$93,710

5%

15%

1.3%

United Technologies (NYSE: UTX  )

$76,205

31%

11%

2.1%

Data provided by Capital IQ and Yahoo! Finance.

From the very beginning, I've talked about diversifying this portfolio not only across company size (small- to large-cap) but also across industry and geography. I already have exposure to retail (lululemon athletica) and food and beverage (Coca-Cola). For my third stock, I'm turning turn to the health-care sector -- and it's nice to see how we are already getting a good bit of diversification with just three buys.

Buying: Abbott and J&J
Make that four buys. Thanks to some prior research I've done, it's quite easy for me to narrow things down, here, and I'll be adding both Abbott Laboratories and Johnson & Johnson to the multivitamin portfolio.

To understand what makes these guys special, we need to take a look at some other screens I've run recently. Both J&J and Abbott have passed my tests for safe, low P/E stocks and highest-yielding stocks you'd actually want to buy. If you click through to those stories, you can see how both have good growth prospects, high quality of earnings, low price-to-earnings multiples, healthy balance sheets, and above-average dividend payouts that are likely to continue growing.

It will be fun to explore the actual businesses in greater detail in future articles, but the highlights are easy. Both have been around for over 120 years and offer a broad -- make that, outstanding -- variety of consumer, health care, and pharmaceutical products. From baby powder to life-saving medicine to extremely complicated medical instruments, these two giants have you covered.

They produce and sell these products at consistently high returns on investment, and rake in gobs (official term) of free cash flow.

They are fine examples of the corporate El Dorados we're seeking. I'm going to start off buying a half position, or about 2.5% of my portfolio, in each company. If you're following along, make sure you have things set up to reinvest the dividends you'll be receiving from these companies. This is very important, and it's the entire reason behind the corporate El Dorado philosophy. For a refresher on this, read and understand this article (don't worry, it's pretty easy).

I'll be talking more about Abbott and J&J in the weeks to come. As always, you can keep up with all my portfolio's comings and goings by following me on Twitter.

This article is part of our Rising Stars Portfolios series, where we give some of our most promising stock analysts cold, hard cash to manage on the Fool's behalf. We'd like you to track our performance and benefit from these real-money, real-time free stock picks. Click here to see all of our Rising Stars analysts (and their portfolios).

Fool analyst Rex Moore once led a horse to water and made him drink. Of the companies mentioned here, he owns shares of Johnson & Johnson and Microsoft. Johnson & Johnson, Coca-Cola, and Microsoft are Motley Fool Inside Value picks. Lululemon Athletica is a Motley Fool Rule Breakers choice. Johnson & Johnson, Coca-Cola, and Procter & Gamble are Motley Fool Income Investor selections. Motley Fool Options has diagonal call positions on Johnson & Johnson and Microsoft. The Fool owns shares of Coca-Cola, ExxonMobil, IBM, Johnson & Johnson, Lululemon Athletica, Microsoft, QUALCOMM, and Schlumberger. Motley Fool Alpha owns shares of Abbott Laboratories and Johnson & Johnson. 

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (3) | Recommend This Article (31)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On February 25, 2011, at 6:32 PM, targetphil2 wrote:

    still waiting on my gout to be cured!

    Hopefully initial positions in coke and abbot will do the trick!

  • Report this Comment On February 27, 2011, at 6:53 AM, stemcellanalyst wrote:

    Might be careful investing in a company with such a lack of diversification away from cardiovascular disease. Stunning results for Cephalon's cardiac stem cell drug were just published in Nature. Revascor reduced MACE (Major Adverse Cardiac Events : chest pain, heart attack, death, etc) by an unprecedented 84%, virtually curing heart disease with one injection. If you can afford it, the drug has already been approved for treatment in Australia. http://bit.ly/i1pYmr

  • Report this Comment On February 28, 2011, at 3:26 PM, coerte wrote:

    How can you go wrong with Fresenius? They offer products for diabetics and this chronic disease is at epidemic proportions and climbing worldwide and they also offer fake limbs for the end game of that particular health problem.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1448722, ~/Articles/ArticleHandler.aspx, 12/22/2014 2:31:14 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement